148 related articles for article (PubMed ID: 31413790)
1. Treatment of Cancer and Alzheimer's Disease by PROTAC Degradation of EGFR.
Kargbo RB
ACS Med Chem Lett; 2019 Aug; 10(8):1098-1099. PubMed ID: 31413790
[No Abstract] [Full Text] [Related]
2. Treatment of Alzheimer's by PROTAC-Tau Protein Degradation.
Kargbo RB
ACS Med Chem Lett; 2019 May; 10(5):699-700. PubMed ID: 31097984
[No Abstract] [Full Text] [Related]
3. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.
Lai AC; Toure M; Hellerschmied D; Salami J; Jaime-Figueroa S; Ko E; Hines J; Crews CM
Angew Chem Int Ed Engl; 2016 Jan; 55(2):807-10. PubMed ID: 26593377
[TBL] [Abstract][Full Text] [Related]
4. Degradation of proteins by PROTACs and other strategies.
Wang Y; Jiang X; Feng F; Liu W; Sun H
Acta Pharm Sin B; 2020 Feb; 10(2):207-238. PubMed ID: 32082969
[TBL] [Abstract][Full Text] [Related]
5. [Targeted degradation of epidermal growth factor receptor in nasopharyngeal carcinoma by chimeric molecule].
Dong J; Li S; Wang Q; Xiao W; Yin SC
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Feb; 31(4):297-300. PubMed ID: 29871246
[No Abstract] [Full Text] [Related]
6. Targeting Epidermal Growth Factor Receptor in Non-Small-Cell-Lung Cancer: Current State and Future Perspective.
Bao SM; Hu QH; Yang WT; Wang Y; Tong YP; Bao WD
Anticancer Agents Med Chem; 2019; 19(8):984-991. PubMed ID: 30868964
[TBL] [Abstract][Full Text] [Related]
7. Monitoring and deciphering protein degradation pathways inside cells.
Daniels DL; Riching KM; Urh M
Drug Discov Today Technol; 2019 Apr; 31():61-68. PubMed ID: 31200861
[TBL] [Abstract][Full Text] [Related]
8. Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC).
Zhang H; Zhao HY; Xi XX; Liu YJ; Xin M; Mao S; Zhang JJ; Lu AX; Zhang SQ
Eur J Med Chem; 2020 Mar; 189():112061. PubMed ID: 31951960
[TBL] [Abstract][Full Text] [Related]
9. Specific MHC-I Peptides Are Induced Using PROTACs.
Jensen SM; Potts GK; Ready DB; Patterson MJ
Front Immunol; 2018; 9():2697. PubMed ID: 30524438
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action.
Riching KM; Mahan S; Corona CR; McDougall M; Vasta JD; Robers MB; Urh M; Daniels DL
ACS Chem Biol; 2018 Sep; 13(9):2758-2770. PubMed ID: 30137962
[TBL] [Abstract][Full Text] [Related]
11. Design of a PROTAC that antagonizes and destroys the cancer-forming X-protein of the hepatitis B virus.
Montrose K; Krissansen GW
Biochem Biophys Res Commun; 2014 Oct; 453(4):735-40. PubMed ID: 25305486
[TBL] [Abstract][Full Text] [Related]
12. Bivalent Ligands for Protein Degradation in Drug Discovery.
Scheepstra M; Hekking KFW; van Hijfte L; Folmer RHA
Comput Struct Biotechnol J; 2019; 17():160-176. PubMed ID: 30788082
[TBL] [Abstract][Full Text] [Related]
13. Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing.
Chhatwal JP; Schultz AP; Johnson KA; Hedden T; Jaimes S; Benzinger TLS; Jack C; Ances BM; Ringman JM; Marcus DS; Ghetti B; Farlow MR; Danek A; Levin J; Yakushev I; Laske C; Koeppe RA; Galasko DR; Xiong C; Masters CL; Schofield PR; Kinnunen KM; Salloway S; Martins RN; McDade E; Cairns NJ; Buckles VD; Morris JC; Bateman R; Sperling RA;
Brain; 2018 May; 141(5):1486-1500. PubMed ID: 29522171
[TBL] [Abstract][Full Text] [Related]
14. Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals).
Schiedel M; Herp D; Hammelmann S; Swyter S; Lehotzky A; Robaa D; Oláh J; Ovádi J; Sippl W; Jung M
J Med Chem; 2018 Jan; 61(2):482-491. PubMed ID: 28379698
[TBL] [Abstract][Full Text] [Related]
15. Inverse relationship between Alzheimer's disease and cancer, and other factors contributing to Alzheimer's disease: a systematic review.
Shafi O
BMC Neurol; 2016 Nov; 16(1):236. PubMed ID: 27875990
[TBL] [Abstract][Full Text] [Related]
16. Targeted protein degradation by PROTACs.
Neklesa TK; Winkler JD; Crews CM
Pharmacol Ther; 2017 Jun; 174():138-144. PubMed ID: 28223226
[TBL] [Abstract][Full Text] [Related]
17. [Effects of Huangpu Tongqiao Capsules on EGFR-PLCγ signal pathway of hippocampus in rats with Alzheimer's disease].
Wang GQ; Zhou P; Xie DJ; Ye S; Gao HW; Wang Y; Fang ZQ; Cai B
Zhongguo Zhong Yao Za Zhi; 2020 May; 45(9):2165-2171. PubMed ID: 32495567
[TBL] [Abstract][Full Text] [Related]
18. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
[TBL] [Abstract][Full Text] [Related]
19. New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation.
Wang X; Feng S; Fan J; Li X; Wen Q; Luo N
Biochem Pharmacol; 2016 Sep; 116():200-9. PubMed ID: 27473774
[TBL] [Abstract][Full Text] [Related]
20. Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
Li Y; Zhang S; Zhang J; Hu Z; Xiao Y; Huang J; Dong C; Huang S; Zhou HB
Eur J Med Chem; 2019 Jun; 172():48-61. PubMed ID: 30939353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
